Smoking and COVID-19: Increased Risk of Severe Complications

Jul.27.2022
Smoking and COVID-19: Increased Risk of Severe Complications
Smoking increases the risk of severe COVID-19 complications and death, according to a study by the American Heart Association.

A new study based on data from the American Heart Association's COVID-19 cardiovascular disease registry has revealed that individuals who smoked or vaped before being hospitalized with COVID-19 are more likely to experience severe complications and even death from SARS-CoV-2 infection compared to those who did not smoke or vape. These findings were published in the peer-reviewed open access scientific journal, PLOS ONE.


Researchers examined data from 107 registered hospitals nationwide on adults aged 18 years and above who were admitted for COVID-19 between January 2020 and March 2021. Smoking status was self-reported, and those who reported using traditional combustible cigarettes or e-cigarette products were classified as smokers without distinction between the two, and without information on smoking duration or previous smoking status. For final analysis, records of 4,086 individuals were selected, with a smoker to nonsmoker ratio of 1:2 (1,362 vs. 2,724), and with no statistical differences in terms of age, gender, race, medical history, or medication between the two groups.


A new study has shown that smoking or using e-cigarettes is linked to more severe cases of COVID-19, regardless of age, gender, race, or medical history.


According to a report, smokers have a 45% higher chance of dying compared to non-smokers, and a 39% higher chance of requiring mechanical ventilation.


While smoking is not related to medical history and drug use, it is a significant risk factor for death in individuals aged 18-59, as well as in Caucasian or obese individuals.


In general, individuals who smoke or use electronic cigarettes often have higher rates of other health conditions and risk factors that could impact how they are affected by COVID-19. However, our research has shown a significant increase in the risk of severe COVID-19, particularly among younger populations, regardless of medical history or drug use. This highlights the urgent need for widespread public health interventions such as anti-smoking campaigns and smoking cessation therapies, especially in the era of COVID-19. "These findings provide the most compelling evidence to date that smokers or users of electronic cigarettes are at higher risk of developing severe COVID-19 and dying from SARS-CoV-2 infection," said Dr. Aruni Bhatnagar, FAHA, senior author of the study and professor of medicine, biochemistry, and molecular biology at the University of Louisville School of Medicine.


Bhatnagar is a co-director of the Tobacco Regulatory Science Center at the American Heart Association, which is partially funded by the United States for this research. The research grants are from the National Institutes of Health and the Food and Drug Administration.


Sandeep R stated, "We established a COVID-19 CVD registry early in the pandemic to better understand the connection between COVID-19 and cardiovascular diseases, particularly in identifying increased risk, in order to provide information to diagnose and care for those at highest risk for complications.


The result of this study has achieved this goal and provided valuable information for individuals and their healthcare teams.


The American Heart Association launched a registry in 2020 to collect specific data on all COVID-19 hospitalized patients as part of the Get With The Guidelines® quality improvement program. All US hospitals caring for adults with active COVID-19 offer free registration and are equipped with infrastructure to support accurate data collection. Between 2020 and June 2022, over 160 hospitals provided data on more than 79,000 patient records.


I am an AI language model designed to generate human-like text. Could you please provide me with the specific text you want me to translate?


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
India has reaffirmed its 2019 ban on e-cigarettes and heated tobacco devices, effectively blocking Philip Morris International (PMI) from launching IQOS in the country despite years of lobbying. Together with Taiwan, China’s conditional opening of heated tobacco products, and Japan’s planned 2026 excise tax hikes, these moves highlight increasingly divergent national regulatory pathways—an external uncertainty shaping PMI’s smoke-free growth trajectory.
Feb.12
Ireland’s 2026 amendment bill to regulate nicotine pouches and tighten rules on vaping products
Ireland’s 2026 amendment bill to regulate nicotine pouches and tighten rules on vaping products
The Irish government has approved the publication of the Public Health (Tobacco Products and Nicotine Inhaling Products) (Amendment) Bill 2026. The bill would ban the sale of nicotine consumption products such as nicotine pouches to those under 18 and further regulate nicotine vaping products.
Mar.05 by 2FIRSTS.ai
Philip Morris Ukraine Says It Will Invest Another USD 10.00 Million in ZYN Nicotine Pouches This Year
Philip Morris Ukraine Says It Will Invest Another USD 10.00 Million in ZYN Nicotine Pouches This Year
Philip Morris said that after investing USD 5.00 million last year to promote its ZYN nicotine pouch brand in Ukraine, it plans to invest another USD 10.00 million this year to develop the nicotine pouch category and launch a new ZYN line.
Apr.08 by 2FIRSTS.ai
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.
Feb.11
UKVIA Says VApril 2026 Will Highlight Consumer Impact of Tobacco and Vapes Bill
UKVIA Says VApril 2026 Will Highlight Consumer Impact of Tobacco and Vapes Bill
The UK Vaping Industry Association said it will launch the ninth annual VApril campaign next month. The association described VApril as the world’s largest vape awareness initiative and said it has for almost a decade supported adult smokers looking to quit through vaping by providing evidence-based information, expert insights and practical guidance
Mar.24 by 2FIRSTS.ai
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Smoore International (6969.HK) released its 2025 results on March 17 and held an investor presentation on the morning of March 18. In morning trade on March 18, the company’s shares fell more than 16% intraday, hitting a low of HK$9.94.
Mar.18 by 2FIRSTS.ai